Known targets — ChEMBL curated mechanism
CHRNA7HTR3AHTR3BHTR3CHTR3DHTR3E
The experimentally established mechanism targets of Facinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 5/20 | 1.00 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.59 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Facinicline SCHEMBL29749748 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL29365997 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL45698 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL45329 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL260915 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL40976 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL29379716 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL261885 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| SCHEMBL4618556 | 0.87 | CHRNA7 (0.77) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| SCHEMBL492170 | 0.87 | CHRNA7 (0.77) | CHRNA7HTR3ANPC1RAB9AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | claimed |
| EP-2945633-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| EP-2945626-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| EP-2945637-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | claimed |
| WO-2014111838-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| WO-2014111837-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| WO-2014111751-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| EP-1543000-B1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2013-03-06 | — | — | EP | claimed |
| US-8252811-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-08-28 | — | — | US | claimed |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2012-04-26 | — | — | US | claimed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | claimed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | claimed |
| JP-2006503851-A | — | — | 2006-02-02 | — | — | JP | claimed |
| EP-1543000-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | claimed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | CHRNA5, CHRNA7, CHRNA3 | CHRNA7 2/4885HTR3A 166/4885NPC1 1448/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885HTR3A 131/4885NPC1 2105/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885HTR3A 151/4885NPC1 638/4885 |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885HTR3A 137/4885NPC1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.